Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus chemotherapy for newly diagnosed AML (age <55)
ChiCTR2200061524Phase 4Recruiting
- Sponsor
- Handan Central Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Handan Central Hospital. Primary endpoint: 5-year overall survival. Started Jan 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200061524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061524.